Pelvic inflammatory disease and reproductive outcomes: an interdisciplinary consensus on pathogenetic therapy. Expert Council resolution

Pelvic inflammatory disease (PID) remains one of the leading causes of chronic pelvic pain, pelvic adhesions, chronic endometritis, tubal-peritoneal infertility and reproductive losses. This resolution summarizes the outcomes of the Expert Council meeting held on July 2, 2026, in Saint Petersburg within the XIX Regional Scientific and Educational Forum "Mother and Child" and presents an interdisciplinary consensus on the pathogenetic therapy of PID. The experts reviewed current data on the epidemiology and polymicrobial etiology of PID, the role of biofilms in infection persistence and reduced efficacy of antibacterial therapy, and the mechanisms underlying chronic endometritis, fibrosis and adhesion formation. Experimental in vivo and in vitro data on the antifibrotic, anti-inflammatory and antibiofilm effects of bovhyaluronidase azoximer were analyzed, together with a systematic review and meta-analysis of 26 controlled clinical trials (n=2111) that demonstrated higher rates of pelvic pain resolution, pathogen elimination, relapse-free course and pregnancy when the drug was added to standard therapy. The experts concluded that antibacterial therapy remains the mandatory basic component of PID treatment, whereas bovhyaluronidase azoximer may be considered a pathogenetically justified component of complex therapy in patients with a clinically significant inflammatory-fibrotic and adhesive component of the disease, within its approved indications. Recommendations for clinical practice, research and medical education are proposed.

Authors

Institutions

Publication Details

Journal
Russian Journal of Human Reproduction
Published
2026-11-18
DOI
https://doi.org/10.17116/repro20263205139
Primary Topic
Reproductive tract infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pelvic inflammatory disease and reproductive outcomes: an interdisciplinary consensus on pathogenetic therapy. Expert Council resolution

Natalia I. Tapilskaya, В.Н. Кузьмин, Yu.E. Dobrokhotova, G.R. Bayramova et al.
Russian Journal of Human Reproduction
Reproductive tract infections research
article

Pelvic inflammatory disease and reproductive outcomes: an interdisciplinary consensus on pathogenetic therapy. Expert Council resolution

Natalia I. Tapilskaya, В.Н. Кузьмин, Yu.E. Dobrokhotova, G.R. Bayramova, Laura G. Pivazyan, Igor I. Baranov, V. V. Korennaya, Gennady Tikhonovich Sukhikh, N.Yu. Katkova, Аполихина Инна Анатольевна, Alevtina Mikhailovna Savicheva, V. F. Bezhenar, Natalya V. Spiridonova, George R. Kasyan, Maria Igorevna Yarmolinskaya, Yu. A. Semenov, Tatyana A. Makarenko, Tatiana V. Priputnevich, Leila V. Adamyan
article en

Abstract

Pelvic inflammatory disease (PID) remains one of the leading causes of chronic pelvic pain, pelvic adhesions, chronic endometritis, tubal-peritoneal infertility and reproductive losses. This resolution summarizes the outcomes of the Expert Council meeting held on July 2, 2026, in Saint Petersburg within the XIX Regional Scientific and Educational Forum "Mother and Child" and presents an interdisciplinary consensus on the pathogenetic therapy of PID. The experts reviewed current data on the epidemiology and polymicrobial etiology of PID, the role of biofilms in infection persistence and reduced efficacy of antibacterial therapy, and the mechanisms underlying chronic endometritis, fibrosis and adhesion formation. Experimental in vivo and in vitro data on the antifibrotic, anti-inflammatory and antibiofilm effects of bovhyaluronidase azoximer were analyzed, together with a systematic review and meta-analysis of 26 controlled clinical trials (n=2111) that demonstrated higher rates of pelvic pain resolution, pathogen elimination, relapse-free course and pregnancy when the drug was added to standard therapy. The experts concluded that antibacterial therapy remains the mandatory basic component of PID treatment, whereas bovhyaluronidase azoximer may be considered a pathogenetically justified component of complex therapy in patients with a clinically significant inflammatory-fibrotic and adhesive component of the disease, within its approved indications. Recommendations for clinical practice, research and medical education are proposed.

Russian Journal of Human ReproductionVol. 32(5)
Privolzhsky Research Medical University (RU), Moscow State University of Medicine and Dentistry (RU), Sechenov University (RU), First Pavlov State Medical University of St. Petersburg (RU), Pirogov Russian National Research Medical University (RU), Research Institute of Obstetrics and Gynecology named after D.O. Ott (RU), Krasnoyarsk State Medical University (RU), Ural State Medical University (RU), Russian Medical Academy of Continuous Professional Education (RU), Ministry of Health of the Russian Federation (RU), Samara State Medical University (RU), National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Healthcare of the Russian Federation (RU), North-Western State Medical University named after I.I. Mechnikov (RU), Saint Petersburg State Pediatric Medical University (RU)
Good health and well-being
Reproductive tract infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon